# Universal Anti-Viral Vaccine for Healthy Elderly Adults

> **NCT04441047** · PHASE1,PHASE2 · COMPLETED · sponsor: **Mirror Biologics, Inc.** · enrollment: 40 (actual)

## Conditions studied

- Virus Diseases
- Pneumonia
- COVID-19 Respiratory Infection
- RSV Pneumonia
- Influenza, Human
- ARDS, Human

## Interventions

- **DRUG:** AlloStim

## Key facts

- **NCT ID:** NCT04441047
- **Lead sponsor:** Mirror Biologics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-12
- **Primary completion:** 2023-03-01
- **Final completion:** 2024-11-01
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2025-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04441047

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04441047, "Universal Anti-Viral Vaccine for Healthy Elderly Adults". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04441047. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*